Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.43 |
| ▸ | CTSS | P25774 | 5/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 5/20 | 0.38 |
| ▸ | PPARA | Q07869 | 5/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.36 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1052501 | 1.00 | CTSK (0.43) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL1052504 | 1.00 | CTSK (0.43) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL6885122 | 0.89 | HDAC4 (0.41) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL25139692 | 0.80 | CTSK (0.46) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL375737 | 0.80 | CTSK (0.46) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL20835669 | 0.78 | CTSK (0.49) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL20835667 | 0.78 | CTSK (0.49) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL25363671 | 0.77 | PPARA (0.44) | CTSKCTSSPPARGPPARAACE | |
| SCHEMBL25363674 | 0.77 | PPARA (0.44) | CTSKCTSSPPARGPPARAACE | |
| SCHEMBL31407449 | 0.77 | CTSK (0.56) | CTSKCTSSHDAC4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-05-18 | — | — | US | disclosed |
| US-20150031106-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-8741837-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130017991-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8293705-B2 | HCV protease inhibitors and uses thereof | AVILA THERAPEUTICS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| WO-2011002808-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CTSK 58/4885CTSS 40/4885HDAC4 1741/4885 |
| US-20150031106-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CTSK 58/4885CTSS 40/4885HDAC4 1741/4885 |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CTSK 58/4885CTSS 40/4885HDAC4 1741/4885 |
| US-20130017991-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CTSK 58/4885CTSS 40/4885HDAC4 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.